Navigation Links
New Antioxidant Drug Shows Promise Against Diabetes
Date:5/23/2008

But more studies on cardiovascular risks needed, report says

FRIDAY, May 23 (HealthDay News) -- A new antioxidant drug shows benefits in the prevention and treatment of diabetes, but more research on possible cardiovascular risks is needed before it is used widely, a new study indicates.

Preliminary results on the drug, succinobucol, have been presented at medical meetings. The full study is published in the May 24 issue of The Lancet.

"There is more data in the article than in the previous presentation, with greater detail on the prevention of diabetes and glycemic [sugar] control," said study author Dr. Jean-Claude Tardif, director of the research center at the Montreal Heart Institute in Canada.

"There are several interesting findings that include a large reduction of new cases of diabetes and also glycemic control in patients who already have diabetes," Tardif said. "But there needs to be confirmation before it is used widely, because there was no effect on clinical endpoints such as heart attack and stroke."

Some confirmation of the drug's effectiveness is expected from a major trial that is nearing completion, Tardif said. Results of that trial should be published "within the next few months," he said.

Succinobucol is a chemical relative of probucol, a cholesterol-lowering drug taken off the market in the United States in 1995 because of side effects. In addition to its antioxidant effects, succinobucol also reduces inflammation.

The trial reported in The Lancet included 6,144 people, 37 percent of whom had diabetes and all of whom had been hospitalized for a heart attack or the dangerous heart rhythm problem called unstable angina. For two years, half of the participants took succinobucol daily, while the other half took a placebo. All were taking other drugs, such as cholesterol-lowering statins, beta blockers or ACE inhibitors.

Among the participants who did not have diabetes when the study began, 4.2 percent of those not taking succinobucol developed the disease, compared to 1.64 percent of those taking the drug, a 64 percent risk reduction. For those with diabetes, taking succinobucol provided better blood sugar control than not taking the drug.

Atrial fibrillation, a dangerous heartbeat abnormality, was twice as likely to develop during the trial in those taking succinobucol. There was no difference in the incidence of death, cardiac arrest, heart attack, stroke or other cardiovascular endpoints between those taking or not taking the drug.

"The study results need confirmation before it is used widely, because there was no effect on those clinical endpoints," Tardif said. "But that is true of all the drugs now used in diabetes. There is no evidence that they reduce heart attacks and strokes."

The chief side effect of the drug was diarrhea, reported by 23 percent of those taking it. One in seven of those reporting diarrhea stopped taking succinobucol.

More information

Currently available drugs for diabetes are described by the American Diabetes Association.



SOURCES: Jean-Claude Tardif, M.D., director, Montreal Heart Institute Research Center, Canada; May 23, 2008, The Lancet


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
2. Antioxidant Supplements May Raise Womens Skin Cancer Risk
3. New research into plant colors sheds light on antioxidants
4. Antioxidants do not prevent degenerative eye disease
5. Major ORAC Differences Among Top Antioxidant Beverages
6. Grape Consumption Improves Antioxidant Capacity in Humans
7. Snapples New Antioxidant Water and LYTeWater Take Hydration to the Next Level
8. Citrus juice, vitamin C give staying power to green tea antioxidants
9. Natural Antioxidants Help Reduce Oxidative Stress in Diabetes Treatment
10. New Research Confirms Wild Blueberry Antioxidant Power
11. Citrus Juice Gives Boost to Green Tea Antioxidants
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Antioxidant Drug Shows Promise Against Diabetes
(Date:6/26/2016)... ... 26, 2016 , ... Brent Kasmer, a legally blind and certified personal trainer is helping to ... app. The fitness app plans to fix the two major problems leading the fitness industry ... fits all type program , They don’t eliminate all the reasons people quit ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
(Date:6/23/2016)... WASHINGTON , June 23, 2016  The ... Pharmaceuticals has joined the health policy research organization ... Steven Romano , MD, senior vice president and ... his company,s representative on the NPC Board of ... are pleased that Mallinckrodt has joined us in ...
Breaking Medicine Technology: